Recro Pharma, Inc. REPH

Set alert

Price alert · REPH

All alert types
2.09 0.00 0.00%

At close

2.00 Day range 2.14

52-week range unavailable

Open
2.07
Prev close
2.09
Mkt cap
177.42M
Vol
137.54K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
2.00
High
2.14
Forward P/E
-11.61
Beta
0.00
Short ratio
5.87
Inst. own
54.96%
Dividend
0.00
Ex-div date
Earnings
May 5, 2022
50-d avg
1.73
200-d avg
1.88
1y target
5.00

MAX chart

Chart tools
Interval

Chart is warming up

The all-time price history for REPH has not been loaded yet. Try again in a moment.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 5.00 +139.2% upside
Target (low)
4.00
Target (mean)
5.00
Target (high)
6.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 3
  • 1 month ago 3
  • 2 months ago 3
  • 3 months ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

REPH analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.09-0.10 – -0.08-0.23+60.9%19.42M+15.6%3
Next quarter-0.03-0.04 – -0.020.03-200.0%25.05M+39.0%3
Current year-0.22-0.23 – -0.20-0.26+15.4%92.12M+22.2%3
Next year-0.18-0.22 – -0.14-0.22+18.2%99.90M+8.4%3

Upgrades and downgrades

The latest rating changes

REPH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2021William BlairInitiated—Outperform
May 12, 2020OppenheimerMaintained—Outperform
Mar 5, 2020Stephens & Co.Maintained—Overweight
Nov 26, 2019Stephens & Co.Maintained—Overweight
Oct 17, 2019Stephens & Co.Initiated—Overweight
Mar 25, 2019Roth CapitalDowngradeBuyNeutral
Feb 14, 2018OppenheimerInitiated—Outperform
Dec 19, 2016PiperJaffrayInitiated—Overweight
Sep 16, 2016Roth CapitalInitiated—Buy
Aug 29, 2016Janney CapitalInitiated—Buy
Sep 2, 2015H.C. WainwrightInitiated—Buy
Jun 18, 2015Brean CapitalMaintained—Buy
Dec 8, 2014Aegis CapitalDowngradeBuyHold
Jun 12, 2014Aegis CapitalInitiated—Buy